Hikma Pharmaceuticals PLC (HIK) - Net Assets
Based on the latest financial reports, Hikma Pharmaceuticals PLC (HIK) has net assets worth GBX2.55 Billion GBX as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX5.55 Billion) and total liabilities (GBX3.00 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX2.55 Billion |
| % of Total Assets | 45.93% |
| Annual Growth Rate | 19.27% |
| 5-Year Change | 8.05% |
| 10-Year Change | 71.67% |
| Growth Volatility | 36.99 |
Hikma Pharmaceuticals PLC - Net Assets Trend (2002–2024)
This chart illustrates how Hikma Pharmaceuticals PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hikma Pharmaceuticals PLC (2002–2024)
The table below shows the annual net assets of Hikma Pharmaceuticals PLC from 2002 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX2.32 Billion | +5.07% |
| 2023-12-31 | GBX2.21 Billion | +2.84% |
| 2022-12-31 | GBX2.15 Billion | -12.93% |
| 2021-12-31 | GBX2.47 Billion | +14.85% |
| 2020-12-31 | GBX2.15 Billion | +0.89% |
| 2019-12-31 | GBX2.13 Billion | +25.46% |
| 2018-12-31 | GBX1.70 Billion | +11.06% |
| 2017-12-31 | GBX1.53 Billion | -36.62% |
| 2016-12-31 | GBX2.41 Billion | +78.33% |
| 2015-12-31 | GBX1.35 Billion | +11.18% |
| 2014-12-31 | GBX1.22 Billion | +17.60% |
| 2013-12-31 | GBX1.03 Billion | +21.96% |
| 2012-12-31 | GBX847.85 Million | +6.16% |
| 2011-12-31 | GBX798.63 Million | +6.44% |
| 2010-12-31 | GBX750.30 Million | +9.81% |
| 2009-12-31 | GBX683.26 Million | +12.19% |
| 2008-12-31 | GBX609.00 Million | +43.41% |
| 2007-12-31 | GBX424.66 Million | +21.40% |
| 2006-12-31 | GBX349.80 Million | +21.68% |
| 2005-12-31 | GBX287.48 Million | +98.02% |
| 2004-12-31 | GBX145.18 Million | +140.07% |
| 2003-12-31 | GBX60.47 Million | +25.91% |
| 2002-12-31 | GBX48.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hikma Pharmaceuticals PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 236200000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | GBX2.36 Billion | 102.25% |
| Common Stock | GBX40.00 Million | 1.73% |
| Total Equity | GBX2.31 Billion | 100.00% |
Hikma Pharmaceuticals PLC Competitors by Market Cap
The table below lists competitors of Hikma Pharmaceuticals PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FORCS Co.Ltd
KQ:189690
|
$37.17 Million |
|
Magna Finance Tbk
JK:MGNA
|
$37.17 Million |
|
HARMONYCHAIN AS NK -05
F:7EW
|
$37.17 Million |
|
Tajiri Resources Corp
V:TAJ
|
$37.18 Million |
|
Seplat Petroleum Development Company PLC
LSE:SEPL
|
$37.15 Million |
|
HOCHDORF HLDG AG
F:1Z3
|
$37.15 Million |
|
SEOJEON ELECTRIC MACHINERY Co.Ltd
KQ:189860
|
$37.14 Million |
|
Podium Minerals Ltd
AU:POD
|
$37.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hikma Pharmaceuticals PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,198,000,000 to 2,310,000,000, a change of 112,000,000 (5.1%).
- Net income of 359,000,000 contributed positively to equity growth.
- Dividend payments of 175,000,000 reduced retained earnings.
- Other comprehensive income increased equity by 282,000,000.
- Other factors decreased equity by 316,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX359.00 Million | +15.54% |
| Dividends Paid | GBX175.00 Million | -7.58% |
| Other Comprehensive Income | GBX282.00 Million | +12.21% |
| Other Changes | GBX-316.00 Million | -13.68% |
| Total Change | GBX- | 5.10% |
Book Value vs Market Value Analysis
This analysis compares Hikma Pharmaceuticals PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 133.42x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4809.55x to 133.42x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | GBX0.29 | GBX1379.00 | x |
| 2003-12-31 | GBX0.36 | GBX1379.00 | x |
| 2004-12-31 | GBX0.86 | GBX1379.00 | x |
| 2005-12-31 | GBX1.83 | GBX1379.00 | x |
| 2006-12-31 | GBX1.96 | GBX1379.00 | x |
| 2007-12-31 | GBX2.37 | GBX1379.00 | x |
| 2008-12-31 | GBX3.12 | GBX1379.00 | x |
| 2009-12-31 | GBX3.49 | GBX1379.00 | x |
| 2010-12-31 | GBX3.78 | GBX1379.00 | x |
| 2011-12-31 | GBX3.93 | GBX1379.00 | x |
| 2012-12-31 | GBX4.21 | GBX1379.00 | x |
| 2013-12-31 | GBX5.14 | GBX1379.00 | x |
| 2014-12-31 | GBX5.99 | GBX1379.00 | x |
| 2015-12-31 | GBX6.65 | GBX1379.00 | x |
| 2016-12-31 | GBX10.24 | GBX1379.00 | x |
| 2017-12-31 | GBX6.31 | GBX1379.00 | x |
| 2018-12-31 | GBX6.96 | GBX1379.00 | x |
| 2019-12-31 | GBX8.71 | GBX1379.00 | x |
| 2020-12-31 | GBX8.97 | GBX1379.00 | x |
| 2021-12-31 | GBX10.53 | GBX1379.00 | x |
| 2022-12-31 | GBX9.49 | GBX1379.00 | x |
| 2023-12-31 | GBX9.88 | GBX1379.00 | x |
| 2024-12-31 | GBX10.34 | GBX1379.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hikma Pharmaceuticals PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.54%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.48%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 2.22x
- Recent ROE (15.54%) is above the historical average (13.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 21.99% | 12.28% | 0.90x | 1.99x | GBX5.72 Million |
| 2003 | 29.28% | 16.73% | 0.89x | 1.96x | GBX11.58 Million |
| 2004 | 26.29% | 17.64% | 0.86x | 1.73x | GBX23.21 Million |
| 2005 | 15.45% | 16.73% | 0.66x | 1.40x | GBX15.48 Million |
| 2006 | 15.80% | 17.20% | 0.65x | 1.42x | GBX20.02 Million |
| 2007 | 14.95% | 13.94% | 0.50x | 2.14x | GBX20.73 Million |
| 2008 | 9.47% | 9.84% | 0.60x | 1.60x | GBX-3.20 Million |
| 2009 | 11.49% | 12.20% | 0.62x | 1.51x | GBX10.09 Million |
| 2010 | 13.29% | 13.52% | 0.66x | 1.50x | GBX24.46 Million |
| 2011 | 10.32% | 8.73% | 0.58x | 2.03x | GBX2.45 Million |
| 2012 | 12.01% | 9.02% | 0.64x | 2.08x | GBX16.73 Million |
| 2013 | 20.85% | 15.53% | 0.71x | 1.90x | GBX110.30 Million |
| 2014 | 23.22% | 18.67% | 0.66x | 1.88x | GBX158.30 Million |
| 2015 | 18.85% | 17.50% | 0.55x | 1.94x | GBX118.30 Million |
| 2016 | 6.47% | 7.95% | 0.45x | 1.82x | GBX-84.60 Million |
| 2017 | -55.68% | -43.54% | 0.57x | 2.24x | GBX-994.40 Million |
| 2018 | 16.74% | 13.62% | 0.59x | 2.08x | GBX113.50 Million |
| 2019 | 22.96% | 22.02% | 0.56x | 1.86x | GBX274.30 Million |
| 2020 | 20.19% | 18.41% | 0.57x | 1.94x | GBX217.50 Million |
| 2021 | 17.16% | 16.49% | 0.58x | 1.78x | GBX175.70 Million |
| 2022 | 8.81% | 7.47% | 0.56x | 2.09x | GBX-25.50 Million |
| 2023 | 8.64% | 6.61% | 0.61x | 2.13x | GBX-29.80 Million |
| 2024 | 15.54% | 11.48% | 0.61x | 2.22x | GBX128.00 Million |
Industry Comparison
This section compares Hikma Pharmaceuticals PLC's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,914,402,347
- Average return on equity (ROE) among peers: -157.88%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hikma Pharmaceuticals PLC (HIK) | GBX2.55 Billion | 21.99% | 1.18x | $37.16 Million |
| MERCK Kommanditgesellschaft auf Aktien (0O14) | $26.75 Billion | 10.56% | 0.81x | $17.92 Billion |
| Allergy Therapeutics (AGY) | $37.77 Million | -36.48% | 0.93x | $7.85 Million |
| Animalcare Group Plc (ANCR) | $15.38 Million | 6.75% | 0.65x | $2.80 Million |
| Alliance Pharma plc (APH) | $7.50 Million | 8.81% | 3.77x | $4.26 Million |
| Beximco Pharmaceuticals Limited (BXP) | $8.25 Billion | 4.28% | 0.45x | $2.31 Million |
| Celadon Pharmaceuticals PLC (CEL) | $99.03K | -1412.59% | 37.89x | $112.25K |
| Chill Brands Group PLC (CHLL) | $-1.23 Million | 0.00% | 0.00x | $33.40K |
| Eco Animal Health Group Plc (EAH) | $95.31 Million | 7.70% | 0.23x | $812.15K |
| HUTCHMED China Ltd (HCM) | $68.81 Million | -9.98% | 1.32x | $23.00 Million |
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and spe… Read more